Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up
1998

Allelic Imbalance at Chromosome 17p13.3 in Breast Cancer

Sample size: 91 publication Evidence: moderate

Author Information

Author(s): AM Thompson, DN Crichton, RA Elton, MF Clay, U Chetty, CM Steel

Hypothesis

Is allelic imbalance at YNZ22 an independent predictor of poor prognosis in breast cancer?

Conclusion

Allelic imbalance at the YNZ22 locus is significantly associated with disease recurrence and reduced survival in breast cancer patients.

Supporting Evidence

  • 41% of patients had disease relapse during follow-up.
  • 25% of patients died during the follow-up period.
  • 52% of informative patients showed allelic imbalance at the YNZ22 locus.
  • Allelic imbalance at YNZ22 was significantly associated with disease recurrence.
  • Allelic imbalance at YNZ22 showed a trend towards impaired survival.

Takeaway

This study found that a specific genetic change in breast cancer is linked to worse outcomes for patients, even if other common genetic changes are not present.

Methodology

The study involved 91 female patients with primary operable breast cancer, examining genetic changes and their association with clinical outcomes over a minimum of 72 months follow-up.

Limitations

The study may have limitations due to the relatively small sample size and the complexity of genetic interactions.

Participant Demographics

91 female patients, mean age 57 years (range 30-78 years) with primary, previously untreated breast cancer.

Statistical Information

P-Value

0.008

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication